Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/DDDT.S113192 http://scihub22266oqcxt.onion/10.2147/DDDT.S113192 C5439982!5439982 !28553077     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28553077 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28553077 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Drug+Des+Devel+Ther 2017 ; 11 (ä): 1473-1480 Nephropedia Template TP {{tp|p=28553077 |t=2017. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy |pdf=|usr=}}{{28553077 }} gab.com Text Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy JO: Drug Des Devel Ther http://www.kidney.de/pget.php?&tw=1&pmid=28553077 #FOAvip Atopic dermatitis (AD) is among the most common inflammatory skin diseases in children and adults in industrialized countries. Up to one-third of adults (probably a smaller proportion in childhood) suffer from moderate-to-severe AD, whose recommended treatment is usually based on systemic therapies. The currently available therapeutics are limited, and AD management becomes challenging in most cases. Over the last few years, new advances in the understanding of AD pathogenic mechanisms and inflammatory pathways have led to the identification of specific therapeutic targets and new molecules have been tested. Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor ? subunit that is able to block the signaling of both IL-4 and IL-13 and achieve rapid and significant improvements in adults with moderate-to-severe AD. Dupilumab is ready to inaugurate a long and promising biological target treatment option for Th2 cell-mediated atopic immune response that characterizes AD. Twit Text FOAVip Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy ????Drug Des Devel Ther http://www.kidney.de/pget.php?&tw=1&pmid=28553077 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28553077 #FOAvip English Wikipedia <ref>{{Cite pmid|28553077 }}</ref> Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy #MMPMID28553077 D'Erme AM ; Romanelli M ; Chiricozzi A Drug Des Devel Ther 2017[]; 11 (ä): 1473-1480 PMID28553077 show ga Atopic dermatitis (AD) is among the most common inflammatory skin diseases in children and adults in industrialized countries. Up to one-third of adults (probably a smaller proportion in childhood) suffer from moderate-to-severe AD, whose recommended treatment is usually based on systemic therapies. The currently available therapeutics are limited, and AD management becomes challenging in most cases. Over the last few years, new advances in the understanding of AD pathogenic mechanisms and inflammatory pathways have led to the identification of specific therapeutic targets and new molecules have been tested. Dupilumab is a fully human monoclonal antibody directed against the IL-4 receptor ? subunit that is able to block the signaling of both IL-4 and IL-13 and achieve rapid and significant improvements in adults with moderate-to-severe AD. Dupilumab is ready to inaugurate a long and promising biological target treatment option for Th2 cell-mediated atopic immune response that characterizes AD. |Adult [MESH] |Antibodies, Monoclonal, Humanized [MESH] |Antibodies, Monoclonal/pharmacology/*therapeutic use [MESH] |Child [MESH] |Dermatitis, Atopic/*drug therapy/immunology/pathology [MESH] |Humans [MESH] |Interleukin-13/antagonists & inhibitors [MESH] |Interleukin-4 Receptor alpha Subunit/*immunology [MESH] |Interleukin-4/antagonists & inhibitors [MESH] |Severity of Illness Index [MESH]Spotlight on dupilumab in the treatment of atopic dermatitis: design, (epmc).pdf DeepDyve Pubget Overpricing